Lawrence T. Kennedy Jr - Jan 3, 2023 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Director, 10%+ Owner
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr.
Stock symbol
BDSX
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 08:20 PM
Previous filing
Jan 5, 2023
Next filing
May 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +91.5K $0.00 91.5K Jan 3, 2023 Common Stock 91.5K Direct F1, F2, F4
transaction BDSX Restricted Stock Units Award $0 +27.4K $0.00 27.4K Jan 3, 2023 Common Stock 27.4K Direct F1, F3, F4
transaction BDSX Stock Options (Right to Buy) Award $0 +125K $0.00 125K Jan 3, 2023 Common Stock 125K $2.05 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer common stock.
F2 These RSUs will vest in full on January 3, 2024, generally subject to the Reporting Person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date.
F3 These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date, and have no expiration date.
F4 Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer.
F5 This option vests 40% on January 3, 2025, and the remaining 60% in 36 successive, equal monthly installments measured from January 3, 2025, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date.